Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 3/2011

01-03-2011 | Editorial

World Kidney Day 2011: Protect your kidneys, save your heart

Authors: William G. Couser, Miguel C. Riella, For the Joint International Society of Nephrology (WGC) and International Federation of Kidney Foundations (MCR) World Kidney Day 2011 Steering Committee

Published in: Pediatric Nephrology | Issue 3/2011

Login to get access

Excerpt

March 10, 2011, will mark the celebration of the 6th World Kidney Day (WKD), an annual event jointly sponsored by the International Society of Nephrology and the International Federation of Kidney Foundations. Since its inception in 2006, WKD has grown dramatically to become the most widely celebrated event associated with kidney disease in the world and the most successful effort to raise awareness among both the general public and government health officials about the dangers of kidney disease, especially chronic kidney disease (CKD). …
Literature
1.
World Health Organization (2005) Preventing Chronic Diseases: A Vital Investment: WHO Global Report. 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases: prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes.
2.
Anderson GF, Chu E (2007) Expanding priorities – Confronting chronic disease in countries with low income. N Engl J Med 356:209–211PubMedCrossRef
3.
Narayan KM, Ali MK, Koplan JP (2010) Global noncommunicable diseases–where worlds meet. N Engl J Med 363:1196–1198PubMedCrossRef
4.
Ritz E, Bakris G, World Kidney Day Organising Committee (2009) World Kidney Day: hypertension and chronic kidney disease. Lancet 373:1157–1158PubMedCrossRef
5.
Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering Committee (2010) Diabetic kidney disease: act now or pay later. Nat Rev Nephrol 6:134–136PubMedCrossRef
6.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–305PubMedCrossRef
7.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17:2034–2047PubMedCrossRef
8.
Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE, de Jong PE (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRef
9.
Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMedCrossRef
10.
van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M, Elhendy A, Poldermans D (2008) Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 19:158–163PubMedCrossRef
11.
Rashidi A, Sehgal AR, Rahman M, O'Connor AS (2008) The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years. Am J Cardiol 102:1668–1673PubMedCrossRef
12.
McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen SC, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT, Kidney Early Evaluation Program Investigators (2008) CKD and Cardiovascular Disease in Screened High-Risk Volunteer and General Populations: The Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 51:S38–S45PubMedCrossRef
13.
McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL, KEEP Investigators (2007) Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 167:1122–1129PubMedCrossRef
14.
McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, Norris KC, McFarlane S, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti J, Whaley-Connell AT, Brenner RM, Bakris GL, Investigators KEEP (2008) Chronic kidney disease: prevalence of premature cardiovascular disease and relationship to short-term mortality. Am Heart J 156:277–283PubMedCrossRef
15.
Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J (2008) Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 167:1226–1233PubMedCrossRef
16.
Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T (2006) The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264–1271PubMedCrossRef
17.
Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ, Investigators CHARM (2009) Individuals at Increased renal risk. J Am Soc Nephrol 20:852–862CrossRef
18.
Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, Cholesterol and Recurrent Events (CARE) Trial Investigators (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332:1426PubMedCrossRef
19.
Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J (2009) Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20:2617–2624PubMedCrossRef
20.
Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki SMalyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobrzycki S (2010) Prevalence of chronic kidney disease in elderly patients with normal serum creatinine levels undergoing percutaneous coronary interventions. Gerontol 56:51–54CrossRef
21.
Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, Alberta Kidney Disease Network (2010) Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303:423–429PubMedCrossRef
22.
Gansevoort RT, de Jong PE (2009) The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 20:465–468PubMedCrossRef
23.
Chronic Kidney Disease Prognosis Consortium (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRef
24.
Abdelhafiz AH, Brown SH, Bello A, El Nahas M (2010) Chronic kidney disease in older people: physiology, pathology or both? Nephron Clin Pract 116:19–24CrossRef
25.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRef
26.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364PubMedCrossRef
27.
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252–1256PubMedCrossRef
28.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863CrossRef
29.
The ESCAPE trial group (2009) Strict blood pressure control and progression of renal failure in children. New Engl J Med 361:1639–1650CrossRef
30.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH (2004) Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809–2816PubMedCrossRef
31.
Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group (2006) Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther 28:432–444PubMedCrossRef
32.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Brenner BM (2004) Albuminuria: a therapeutic target for cardiovascular protection in type 2 diabetic nephropathy. Circulation 110:921–927PubMedCrossRef
33.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D (2007) Albuminuria is a target for renoprotective therapy independent from blood pressure in type II diabetic patients with nephropathy. Post hoc analysis from the Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18:1540–1546PubMedCrossRef
34.
Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators, (2009) Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20:893–900PubMedCrossRef
35.
Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G (2009) Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19:999–1007CrossRef
36.
Fried L (2009) Are we ready to screen the general population for microalbuminuria? J Am Soc Nephrol 20:686–688PubMedCrossRef
37.
El Nahas M (2005) The global challenge of chronic kidney disease. (Nephrology Forum) Kidney Int 68:2918–2929CrossRef
38.
39.
Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, Centers for Disease Control and Prevention Expert Panel (2009) Comprehensive public health strategies for preventing the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis 53:522–535PubMedCrossRef
40.
James MT, Hemmelgarn BR, Tonelli M (2010) Early recognition and prevention of CKD. Lancet 379:1296–1309CrossRef
41.
Perico N, Bravo RF, De Leon FR, Remuzzi G (2009) Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant 24:1355–1358PubMedCrossRef
Metadata
Title
World Kidney Day 2011: Protect your kidneys, save your heart
Authors
William G. Couser
Miguel C. Riella
For the Joint International Society of Nephrology (WGC) and International Federation of Kidney Foundations (MCR) World Kidney Day 2011 Steering Committee
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 3/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-010-1754-0

Other articles of this Issue 3/2011

Pediatric Nephrology 3/2011 Go to the issue

Original Article

Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria

Letter to the Editors

Early identification of steroid dependency in Japanese children with steroid-sensitive nephrotic syndrome undergoing short-term initial steroid therapy

Brief Report

Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration

Educational Review

Microvascular disease in children and adolescents with type 1 diabetes and obesity

Clinical quiz

Four family cases of acute renal failure: question

Original Article

Hepatic and pulmonary nodular lesions in pediatric urinary tract infections